UPDATE 2-Bristol-Myers Squibb wins antitrust approval to buy Celgene, but must divest psoriasis drug
November 15, 2019 at 18:01 PM EST
Bristol-Myers Squibb Co and Celgene Corp have won U.S. antitrust approval for their merger on condition that they sell Celgene's psoriasis drug Otezla, the Federal Trade Commission said in a statement on Friday.
